Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 10:19 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Highlights Advancements in Lipodystrophy Research at ENDO 2026

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases,...
June 09, 2026 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Announces Health Canada Grants Priority Review for FILSUVEZ® (birch triterpenes) Topical Gel for the Treatment of Epidermolysis Bullosa

Priority review recognizes the serious nature of epidermolysis bullosa (EB) and the urgent need for continued evaluation of potential treatment options If approved, FILSUVEZ has the potential to...
June 05, 2026 02:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)

PARMA, Italy, June 05, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare...
June 03, 2026 02:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases to Launch the Second Edition of Find For Rare at 2026 ERA Congress to Advance Research in Lysosomal Storage Disorders

-- At ERA 2026, Chiesi will contribute to advancing the scientific understanding of Fabry disease and nephropathic cystinosis through real-world experience and clinical outcomes, supporting the needs...
March 30, 2026 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Receives Positive CHMP Opinion for LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)

Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of...
March 09, 2026 08:30 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼

Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those...
March 09, 2026 06:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the...
March 03, 2026 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)

Approval expands indication of JUXTAPID® to include children 2 years of age and older with HoFH This announcement was made during the week of Rare Disease Day, which aims to raise awareness about the...
February 05, 2026 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™

-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage...
February 05, 2026 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™

-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage...